Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
8 pending office actions • 7 clients • 7 examiners • 7 art units • 0 of 8 (0%) have an AI response strategy ready
UltimatEdge IP Law Group, P.C. has 8 pending office actions in Biotechnology & Pharmaceuticals and 619 career applications. The open workload can therefore be read alongside a reported application base, although the figures describe different stages of prosecution.
The resolved allowance rate is 86.64%, and the average is 2.81 office actions per allowance. This indicates that resolved matters generally require multiple examination exchanges, while the reported allowance rate shows that many reach an allowed result.
For practitioners, the profile provides both workload and outcome context. The application total helps frame the practice’s recorded activity, while the allowance and office-action measures are relevant when setting expectations for prosecution duration and response planning.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (12%) |
| §103 only | 3 (38%) |
| Double-patenting + other | 3 (38%) |
| Multi-statute (no §101) | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TCHERKASSKAYA, OLGA V | 2 | 55.5% | +46.4% |
| THOMPSON, CURTIS A | 1 | 61.2% | +51.6% |
| BOWERS, ERIN M | 1 | 54.7% | +9.8% |
| BREEN, KIMBERLY CATHERINE | 1 | 23.8% | +56.3% |
| HARTMANN, GARY S | 1 | 72.6% | +19.1% |
| FULTON, MICHAEL TIMOTHY | 1 | 71.4% | +6.3% |
| PETRITSCH, AMANDA MICHELLE | 1 | 56.6% | +25.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18392498 | Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration | BREEN, KIMBERLY CATHERINE | 29d overdue |
| 19385776 | Planar Motor Transport and System for Scalable, Multi-Purpose Lab Automation with Distributed Control Architecture and Temporal Reservation Management | THOMPSON, CURTIS A | — |
| 18487680 | Selectively Frictionally Engaged Hole Cover | HARTMANN, GARY S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18392498 | Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration | BREEN, KIMBERLY CATHERINE | 29d overdue |
| 19385776 | Planar Motor Transport and System for Scalable, Multi-Purpose Lab Automation with Distributed Control Architecture and Temporal Reservation Management | THOMPSON, CURTIS A | — |
| 18978365 | Self-Retaining Implantable Drug Delivery Device | TCHERKASSKAYA, OLGA V | — |
| 18847245 | Compositions Having Improved Bioavailability of Therapeutics and Uses Thereof | TCHERKASSKAYA, OLGA V | — |
| 18487680 | Selectively Frictionally Engaged Hole Cover | HARTMANN, GARY S | — |
| 17596570 | Compositions, Kits, Methods and Uses for Preventing Microbial Growth | PETRITSCH, AMANDA MICHELLE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Med Progress, LLC | 2 |
| Lab Sync Inc. | 1 |
| Goldenbiotech, LLC | 1 |
| Trx Biosciences Limited | 1 |
| Clover Equipment | 1 |
| INFLOWVENT LTD. | 1 |
| Collidion | 1 |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| 1798 | 1 |
| 1653 | 1 |
| 1657 | 1 |
| 3671 | 1 |
| 1747 | 1 |
| 1612 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19385776 | Planar Motor Transport and System for Scalable, Multi-Purpose Lab Automation with Distributed Control Architecture and Temporal Reservation Management | Lab Sync Inc. | THOMPSON, CURTIS A | 1798 | §102§103§112 | Final Rejection | — | Pending | Nov 11, 2025 |
| 18978365 | Self-Retaining Implantable Drug Delivery Device | Goldenbiotech, LLC | TCHERKASSKAYA, OLGA V | 1615 | §103DP | Non-Final OA | — | Pending | Dec 12, 2024 |
| 18847245 | Compositions Having Improved Bioavailability of Therapeutics and Uses Thereof | Trx Biosciences Limited | TCHERKASSKAYA, OLGA V | 1615 | §103§112DP | Non-Final OA | — | Pending | Sep 14, 2024 |
| 18693468 | Reducing or Inhibiting Tissue Damage Using Hyaluronidase Administration | Med Progress, LLC | BOWERS, ERIN M | 1653 | §103DP | Final Rejection | 3d overdue | Pending | Mar 19, 2024 |
| 18392498 | Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration | Med Progress, LLC | BREEN, KIMBERLY CATHERINE | 1657 | §103 | Final Rejection | 29d overdue | Pending | Dec 21, 2023 |
| 18487680 | Selectively Frictionally Engaged Hole Cover | Clover Equipment, LLC | HARTMANN, GARY S | 3671 | §101DP | Final Rejection | — | Pending | Oct 16, 2023 |
| 18031109 | A DEVICE AND A METHOD FOR VAPORISING A VOLATILE MATERIAL | Inflowvent Ltd. | FULTON, MICHAEL TIMOTHY | 1747 | §103 | Final Rejection | 66d overdue | Pending | Apr 10, 2023 |
| 17596570 | Compositions, Kits, Methods and Uses for Preventing Microbial Growth | Collidion, Inc. | PETRITSCH, AMANDA MICHELLE | 1612 | §103 | Final Rejection | — | Pending | Dec 13, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial86.6% of resolved applications prosecuted by Ultimatedge Ip Law Group, P.C. were allowed, across 619 applications in USPTO records.
2.81 office actions per allowed application on average.
8 pending office actions as of October 2026, for 7 clients, before 7 examiners in 7 art units.
